Apr 25, 2022

  • Corporate

F. Hoffmann-La Roche Announces First Quarter Sales 2022

Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (Prime Market of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
President & CEO: Osamu Okuda
Inquiries to: Toshiya Sasai
Head of Corporate Communications Dept.
Tel:+81-(0)3-3273-0554

F. Hoffmann-La Roche Ltd. (hereafter “Roche”) [Head Office: Basel, Switzerland. CEO: Severin Schwan] announced today its first quarter sales 2022 (January 1 – March 31, 2022).

Roche owns 59.89% of Chugai’s outstanding shares (61.16% of voting rights) as of the end of December 2021.

Its investor update and presentation materials can be found on its website (https://www.roche.com/).
Chugai’s performance for the period of January 1 to March 31, 2022 is included in the announced Roche Group’s results.

Investor Updates Reporting

Contact:

  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Takayuki Sakurai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp
  • Like
  • Post
  • LINE it!
  • E-mail
Back to top